Full TitleA Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma (NCI Protocol #9111)
Uveal melanoma is a rare eye cancer. When it is confined to the eye, it can be treated with surgery and radiation therapy. But when it spreads, it is more difficult to treat successfully. The purpose of this study is to evaluate the safety and effectiveness of vorinostat for treating metastatic uveal melanoma.
Vorinostat is approved for treating a form of lymphoma, but its use for uveal melanoma is considered investigational. It is a drug called a histone deacetylase inhibitor, which prevents cancer cells from reproducing by interfering with certain signaling pathways. Vorinostat is a capsule that is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have metastatic uveal melanoma.
- Patients may have had prior treatment with any number of therapies.
- At least 3 weeks must have passed since completion of prior systemic therapy and entry into the study (6 weeks for anti-CTLA4 therapies, BCNU, or mitomycin C).
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Paul Chapman at 646-888-4162.